32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect

Dinesh Chandra, Benson Chellakkan Selvanesan, Ziqiang Yuan, Steven K. Libutti, Wade Koba, Amanda Beck, Kun Zhu, Arturo Casadevall, Ekaterina Dadachova, Claudia Gravekamp

Research output: Contribution to journalArticle

Abstract

Our laboratory has developed a novel delivery platform using an attenuated non-toxic and non-pathogenic bacterium Listeria monocytogenes that infects tumor cells and selectively survives and multiplies in metastases and primary tumors with help of myeloid-derived suppressor cells (MDSC) and immune suppression in the tumor microenvironment (TME). 32P was efficiently incorporated into the Listeria bacteria by starvation of the bacteria in saline, and then cultured in phosphorus-free medium complemented with 32P as a nutrient. Listeria-32P kills tumor cells through both 32P-induced ionizing radiation and Listeria-induced reactive oxygen species (ROS). The levels of 32P and Listeria were studied in various normal and tumor tissues, at sequential time points after injection of mice with pancreatic cancer (syngeneic model Panc-02). We found that 32P and Listeria predominantly accumulated in tumors and metastases, with their highest accumulation 4 hrs (32P) and 3 days (Listeria) after injection. Listeria also penetrated the transgenic KPC (conditionally express endogenous Kras-G12D and p53-R172H mutant alleles) pancreatic tumors and metastases. This is remarkable since KPC tumors, like human tumors, exhibit a stromal barrier, which prevents most drugs from penetrating the pancreatic tumors. Therapeutic treatment with Listeria -32P resulted in a strong reduction of the growth of pancreatic cancer at early and late stages in Panc-02 and KPC mice. These results highlight the power of Listeria as new delivery platform of anticancer agents to the TME. Not only were therapeutic levels of radioactive Listeria reached in tumors and metastases but the selective delivery also led to minimal side effects.

Original languageEnglish (US)
Pages (from-to)20729-20740
Number of pages12
JournalOncotarget
Volume8
Issue number13
DOIs
StatePublished - 2017

Fingerprint

Listeria
Pancreatic Neoplasms
Phosphorus
Neoplasms
Neoplasm Metastasis
Bacteria
Tumor Microenvironment
Listeria monocytogenes
Starvation
Ionizing Radiation
Antineoplastic Agents
Reactive Oxygen Species
Alleles
Food

Keywords

  • P
  • Delivery platform
  • KPC
  • Listeria monocytogenes
  • Panc-02
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. / Chandra, Dinesh; Selvanesan, Benson Chellakkan; Yuan, Ziqiang; Libutti, Steven K.; Koba, Wade; Beck, Amanda; Zhu, Kun; Casadevall, Arturo; Dadachova, Ekaterina; Gravekamp, Claudia.

In: Oncotarget, Vol. 8, No. 13, 2017, p. 20729-20740.

Research output: Contribution to journalArticle

Chandra, D, Selvanesan, BC, Yuan, Z, Libutti, SK, Koba, W, Beck, A, Zhu, K, Casadevall, A, Dadachova, E & Gravekamp, C 2017, '32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect' Oncotarget, vol 8, no. 13, pp. 20729-20740. DOI: 10.18632/oncotarget.15117

Chandra, Dinesh; Selvanesan, Benson Chellakkan; Yuan, Ziqiang; Libutti, Steven K.; Koba, Wade; Beck, Amanda; Zhu, Kun; Casadevall, Arturo; Dadachova, Ekaterina; Gravekamp, Claudia / 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect.

In: Oncotarget, Vol. 8, No. 13, 2017, p. 20729-20740.

Research output: Contribution to journalArticle

@article{db7bd60c42d84bbeb0f6999d6dffc513,
title = "32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect",
abstract = "Our laboratory has developed a novel delivery platform using an attenuated non-toxic and non-pathogenic bacterium Listeria monocytogenes that infects tumor cells and selectively survives and multiplies in metastases and primary tumors with help of myeloid-derived suppressor cells (MDSC) and immune suppression in the tumor microenvironment (TME). 32P was efficiently incorporated into the Listeria bacteria by starvation of the bacteria in saline, and then cultured in phosphorus-free medium complemented with 32P as a nutrient. Listeria-32P kills tumor cells through both 32P-induced ionizing radiation and Listeria-induced reactive oxygen species (ROS). The levels of 32P and Listeria were studied in various normal and tumor tissues, at sequential time points after injection of mice with pancreatic cancer (syngeneic model Panc-02). We found that 32P and Listeria predominantly accumulated in tumors and metastases, with their highest accumulation 4 hrs (32P) and 3 days (Listeria) after injection. Listeria also penetrated the transgenic KPC (conditionally express endogenous Kras-G12D and p53-R172H mutant alleles) pancreatic tumors and metastases. This is remarkable since KPC tumors, like human tumors, exhibit a stromal barrier, which prevents most drugs from penetrating the pancreatic tumors. Therapeutic treatment with Listeria -32P resulted in a strong reduction of the growth of pancreatic cancer at early and late stages in Panc-02 and KPC mice. These results highlight the power of Listeria as new delivery platform of anticancer agents to the TME. Not only were therapeutic levels of radioactive Listeria reached in tumors and metastases but the selective delivery also led to minimal side effects.",
keywords = "P, Delivery platform, KPC, Listeria monocytogenes, Panc-02, Pancreatic cancer",
author = "Dinesh Chandra and Selvanesan, {Benson Chellakkan} and Ziqiang Yuan and Libutti, {Steven K.} and Wade Koba and Amanda Beck and Kun Zhu and Arturo Casadevall and Ekaterina Dadachova and Claudia Gravekamp",
year = "2017",
doi = "10.18632/oncotarget.15117",
volume = "8",
pages = "20729--20740",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "13",

}

TY - JOUR

T1 - 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect

AU - Chandra,Dinesh

AU - Selvanesan,Benson Chellakkan

AU - Yuan,Ziqiang

AU - Libutti,Steven K.

AU - Koba,Wade

AU - Beck,Amanda

AU - Zhu,Kun

AU - Casadevall,Arturo

AU - Dadachova,Ekaterina

AU - Gravekamp,Claudia

PY - 2017

Y1 - 2017

N2 - Our laboratory has developed a novel delivery platform using an attenuated non-toxic and non-pathogenic bacterium Listeria monocytogenes that infects tumor cells and selectively survives and multiplies in metastases and primary tumors with help of myeloid-derived suppressor cells (MDSC) and immune suppression in the tumor microenvironment (TME). 32P was efficiently incorporated into the Listeria bacteria by starvation of the bacteria in saline, and then cultured in phosphorus-free medium complemented with 32P as a nutrient. Listeria-32P kills tumor cells through both 32P-induced ionizing radiation and Listeria-induced reactive oxygen species (ROS). The levels of 32P and Listeria were studied in various normal and tumor tissues, at sequential time points after injection of mice with pancreatic cancer (syngeneic model Panc-02). We found that 32P and Listeria predominantly accumulated in tumors and metastases, with their highest accumulation 4 hrs (32P) and 3 days (Listeria) after injection. Listeria also penetrated the transgenic KPC (conditionally express endogenous Kras-G12D and p53-R172H mutant alleles) pancreatic tumors and metastases. This is remarkable since KPC tumors, like human tumors, exhibit a stromal barrier, which prevents most drugs from penetrating the pancreatic tumors. Therapeutic treatment with Listeria -32P resulted in a strong reduction of the growth of pancreatic cancer at early and late stages in Panc-02 and KPC mice. These results highlight the power of Listeria as new delivery platform of anticancer agents to the TME. Not only were therapeutic levels of radioactive Listeria reached in tumors and metastases but the selective delivery also led to minimal side effects.

AB - Our laboratory has developed a novel delivery platform using an attenuated non-toxic and non-pathogenic bacterium Listeria monocytogenes that infects tumor cells and selectively survives and multiplies in metastases and primary tumors with help of myeloid-derived suppressor cells (MDSC) and immune suppression in the tumor microenvironment (TME). 32P was efficiently incorporated into the Listeria bacteria by starvation of the bacteria in saline, and then cultured in phosphorus-free medium complemented with 32P as a nutrient. Listeria-32P kills tumor cells through both 32P-induced ionizing radiation and Listeria-induced reactive oxygen species (ROS). The levels of 32P and Listeria were studied in various normal and tumor tissues, at sequential time points after injection of mice with pancreatic cancer (syngeneic model Panc-02). We found that 32P and Listeria predominantly accumulated in tumors and metastases, with their highest accumulation 4 hrs (32P) and 3 days (Listeria) after injection. Listeria also penetrated the transgenic KPC (conditionally express endogenous Kras-G12D and p53-R172H mutant alleles) pancreatic tumors and metastases. This is remarkable since KPC tumors, like human tumors, exhibit a stromal barrier, which prevents most drugs from penetrating the pancreatic tumors. Therapeutic treatment with Listeria -32P resulted in a strong reduction of the growth of pancreatic cancer at early and late stages in Panc-02 and KPC mice. These results highlight the power of Listeria as new delivery platform of anticancer agents to the TME. Not only were therapeutic levels of radioactive Listeria reached in tumors and metastases but the selective delivery also led to minimal side effects.

KW - P

KW - Delivery platform

KW - KPC

KW - Listeria monocytogenes

KW - Panc-02

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85016440149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016440149&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15117

DO - 10.18632/oncotarget.15117

M3 - Article

VL - 8

SP - 20729

EP - 20740

JO - Oncotarget

T2 - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -